Form 4 · Statement of Changes in Beneficial Ownership · Filed 2026-06-24
Venker Eric Files Roivant Sciences Ltd (ROIV) Form 4 - June 24, 2026
Venker Eric traded 400.0K ROIV shares worth $7.4M in this Form 4 filing, reported to the SEC on 2026-06-24.
- Insider
- Venker Eric
- Issuer
- Roivant Sciences Ltd ROIV · NASDAQ
- Filed
- Period
- 2026-06-24
- Accession
- 0001635088-26-000071
- Source
- Official filing on sec.gov ↗
Transactions (4)
| Insider | Date | Type | Shares | Price | Value | Own |
|---|---|---|---|---|---|---|
| Venker Eric | 2026-06-24 | Buy | 200.0K | $3.85 | $770.0K | Direct |
| Venker Eric | 2026-06-24 | Sell | 153.8K | $33.05 | $5.1M | Direct |
| Venker Eric | 2026-06-24 | Sell | 46.2K | $33.51 | $1.5M | Direct |
| Net change | 0 | −$5.9M | ||||
About Roivant Sciences Ltd
Roivant Sciences Ltd is a biopharmaceutical company focused on developing and commercializing innovative therapies through a unique model that emphasizes rapid and efficient drug delivery. As a platform company, Roivant Sciences incubates subsidiaries known as 'Vants,' each concentrating on a specific therapeutic area. This model allows Roivant to prioritize development of pharmaceuticals in critical areas, including neurology, oncology, immunology, and others. Roivant’s approach facilitates agility in drug development, enabling each Vant to operate semi-autonomously to accelerate research and commercialization efforts. By leveraging technology and data analytics, Roivant enhances drug discovery processes and optimizes clinical trials. In the pharmaceutical industry, Roivant Sciences represents a forward-thinking entity that addresses unmet medical needs by transforming the traditional paradigms of drug development. Its initiatives have substantial implications for healthcare, potentially altering treatment landscapes and improving patient outcomes globally. Founded in 2014 and headquartered in New York City, Roivant is a notable example of innovation-driven pharmaceutical enterprise in the financial market.
Track ROIV insider activity
Get alerted when Roivant Sciences Ltd executives buy or sell their shares.